Ruth M O'Regan MD

Oncology•Rochester, NY

Breast Cancer

Professor and Chair of Medicine

Join to View Full Profile

601 Elmwood AveRochester, NY 14642
Phone+1 585-275-7938
Fax+1 585-486-0649

Education & Training

McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1998 - 1999
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1995 - 1998
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1994 - 1995
University College of Dublin National Univ SOMClass of 1988

Certifications & Licensure

NY State Medical License 2021 - 2026
WI State Medical License 2015 - 2025
GA State Medical License 2003 - 2017
IL State Medical License 1995 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Atlanta Magazine: Top Doctors Castle Connolly, 2007, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013

Clinical Trials

Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer Start of enrollment: 2006 Dec 01
Unknown status
Phase 2
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores Start of enrollment: 2009 Apr 01
Terminated
Phase 2
Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer Start of enrollment: 2009 May 01
Completed
Phase 2
Re-expression of ER in Triple Negative Breast Cancers Start of enrollment: 2010 Jul 01
Terminated
Phase 1, Phase 2
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
ACTIVE_NOT_RECRUITING
PHASE3
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
COMPLETED
PHASE2
Ribociclib and Bicalutamide in AR+ TNBC Start of enrollment: 2018 May 07
RECRUITING
PHASE1, PHASE2
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer Start of enrollment: 2018 Nov 13
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
When the personal becomes political: The impact of the Dobbs decision on women with cancer.
Jane Lowe Meisel, Amy Harrington, Natalie Whaley, Wendy Vitek, Ruth M O'Regan
Cancer. 2023-01-15
7 citations
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).
Ticiana A Leal, Marina N Sharifi, Nancy Chan, Robert Wesolowski, Anita A Turk
Cancer Medicine. 2022-11-01
2 citations
Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.
David Hicks, Ruth M O'Regan
Journal of Clinical Oncology. 2022-04-10

Lectures

Evolving Approaches in Systemic Therapy for Triple-Negative Breast Cancer in Neoadjuvant and Adjuvant Settings.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Study TTC-352-101: Phase 1 study of TTC-352 in patients with metastatic breast cancer (BC) progressing on endocrine therapy.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Assay Predicts Breast Cancer Patients Who Will Benefit from Ovarian SuppressionDecember 7th, 2022
New Options for Metastatic HER2-Positive Breast CancerJanuary 18th, 2022
Using Genomic Profiling to Select the Right Therapy for Metastatic Breast CancerJanuary 11th, 2022
Join now to see all